ES261175A1 - Procedimiento para la preparaciën de un vector farmaceutico - Google Patents
Procedimiento para la preparaciën de un vector farmaceuticoInfo
- Publication number
- ES261175A1 ES261175A1 ES0261175A ES261175A ES261175A1 ES 261175 A1 ES261175 A1 ES 261175A1 ES 0261175 A ES0261175 A ES 0261175A ES 261175 A ES261175 A ES 261175A ES 261175 A1 ES261175 A1 ES 261175A1
- Authority
- ES
- Spain
- Prior art keywords
- glyoxal
- copolymer
- gelatin
- weight
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 title abstract 14
- 108010010803 Gelatin Proteins 0.000 title abstract 8
- 229920000159 gelatin Polymers 0.000 title abstract 8
- 239000008273 gelatin Substances 0.000 title abstract 8
- 235000019322 gelatine Nutrition 0.000 title abstract 8
- 235000011852 gelatine desserts Nutrition 0.000 title abstract 8
- 229920001577 copolymer Polymers 0.000 title abstract 7
- 229940015043 glyoxal Drugs 0.000 title abstract 7
- 239000003937 drug carrier Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 4
- 239000007787 solid Substances 0.000 abstract 4
- 239000000243 solution Substances 0.000 abstract 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 abstract 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 abstract 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 abstract 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 abstract 1
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 abstract 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract 1
- 229930003347 Atropine Natural products 0.000 abstract 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 abstract 1
- 239000004099 Chlortetracycline Substances 0.000 abstract 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 1
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 abstract 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 abstract 1
- 239000004100 Oxytetracycline Substances 0.000 abstract 1
- 229930182555 Penicillin Natural products 0.000 abstract 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 239000004098 Tetracycline Substances 0.000 abstract 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 abstract 1
- 229960001301 amobarbital Drugs 0.000 abstract 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 230000002921 anti-spasmodic effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 229960000396 atropine Drugs 0.000 abstract 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 abstract 1
- 229960002319 barbital Drugs 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 abstract 1
- 229960002155 chlorothiazide Drugs 0.000 abstract 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 abstract 1
- 229960001076 chlorpromazine Drugs 0.000 abstract 1
- 229960004475 chlortetracycline Drugs 0.000 abstract 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 abstract 1
- 235000019365 chlortetracycline Nutrition 0.000 abstract 1
- 239000000812 cholinergic antagonist Substances 0.000 abstract 1
- 229960004544 cortisone Drugs 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960002222 dihydrostreptomycin Drugs 0.000 abstract 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 229960003210 hyoscyamine Drugs 0.000 abstract 1
- 229930005342 hyoscyamine Natural products 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 229960004815 meprobamate Drugs 0.000 abstract 1
- TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 229960000625 oxytetracycline Drugs 0.000 abstract 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 abstract 1
- 235000019366 oxytetracycline Nutrition 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 229940049954 penicillin Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 abstract 1
- 229960002695 phenobarbital Drugs 0.000 abstract 1
- 238000006116 polymerization reaction Methods 0.000 abstract 1
- 230000000379 polymerizing effect Effects 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- -1 pregnisolone Chemical compound 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 229940018203 pyrilamine maleate Drugs 0.000 abstract 1
- 229960005322 streptomycin Drugs 0.000 abstract 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 abstract 1
- 229960004306 sulfadiazine Drugs 0.000 abstract 1
- 229960002597 sulfamerazine Drugs 0.000 abstract 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 abstract 1
- ASWVTGNCAZCNNR-UHFFFAOYSA-N sulfamethazine Chemical compound CC1=CC(C)=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ASWVTGNCAZCNNR-UHFFFAOYSA-N 0.000 abstract 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 abstract 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 229960002180 tetracycline Drugs 0.000 abstract 1
- 235000019364 tetracycline Nutrition 0.000 abstract 1
- 229930101283 tetracycline Natural products 0.000 abstract 1
- 150000003522 tetracyclines Chemical class 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 229960003223 tripelennamine Drugs 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09H—PREPARATION OF GLUE OR GELATINE
- C09H7/00—Preparation of water-insoluble gelatine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S8/00—Bleaching and dyeing; fluid treatment and chemical modification of textiles and fibers
- Y10S8/17—Glyoxal and polyaldehyde treatment of textiles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Procedimiento para la preparación de un vector farmacéutico conveniente para administración oral, que comprende polimerizar la gelatina hidrolizada con alrededor de 2.5 a alrededor de 7% por peso de glioxal basado en el peso de la gelatina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US843631A US3028308A (en) | 1959-10-01 | 1959-10-01 | Dry pharmaceutical vehicle of copolymer of hydrolyzed gelatin and glyoxal, and its production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES261175A1 true ES261175A1 (es) | 1961-04-01 |
Family
ID=25290563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES0261175A Expired ES261175A1 (es) | 1959-10-01 | 1960-09-21 | Procedimiento para la preparaciën de un vector farmaceutico |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3028308A (es) |
| BE (1) | BE595413A (es) |
| CH (1) | CH394494A (es) |
| DE (1) | DE1445105A1 (es) |
| ES (1) | ES261175A1 (es) |
| GB (1) | GB948008A (es) |
| NL (2) | NL125158C (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL128945C (es) * | 1960-05-27 | |||
| US3171831A (en) * | 1961-02-14 | 1965-03-02 | Schwarz Biores Inc | Thiolation of proteins by reaction with homocysteine thiolactone in the presence of tertiary amine |
| US3247066A (en) * | 1962-09-12 | 1966-04-19 | Parke Davis & Co | Controlled release dosage form containing water-swellable beadlet |
| US3239420A (en) * | 1962-10-11 | 1966-03-08 | Vitamix Pharmaceuticals Inc | Gelatin composition |
| BE629985A (es) * | 1962-11-29 | |||
| US3329574A (en) * | 1965-04-12 | 1967-07-04 | Schwarz Biores Inc | Method and material for selective diffusion |
| US3480435A (en) * | 1965-08-19 | 1969-11-25 | Adam T Krol | Production of printing plates and the like |
| US3301692A (en) * | 1966-02-14 | 1967-01-31 | Wilson & Co Inc | Process of treating proteins and the product thereof |
| US3489838A (en) * | 1967-10-19 | 1970-01-13 | Phillips Petroleum Co | Repelling birds |
| US3666678A (en) * | 1968-01-12 | 1972-05-30 | Benjamin Mosier | Process of encapsulating basic nitrogen compounds with acid-precursor gelatin |
| FR2407720A1 (fr) * | 1977-11-08 | 1979-06-01 | Lipha Lyonnaise Indle Pharmace | Preparations pharmaceutiques orales a activite therapeutique prolongee |
| US4389419A (en) * | 1980-11-10 | 1983-06-21 | Damon Corporation | Vitamin encapsulation |
| JPS6021764A (ja) * | 1983-07-14 | 1985-02-04 | 日立化成工業株式会社 | ゼラチン球状粒子の製造法 |
| DE3466702D1 (en) * | 1983-07-14 | 1987-11-12 | Hitachi Chemical Co Ltd | Gelatin spherical gels and production thereof |
| CA1335748C (en) * | 1986-09-25 | 1995-05-30 | Jeffrey Lawrence Finnan | Crosslinked gelatins |
| US5108762A (en) * | 1989-04-19 | 1992-04-28 | Wm. Wrigley Jr. Company | Gradual release structures for chewing gum |
| US5165944A (en) * | 1989-04-19 | 1992-11-24 | Wm. Wrigley Jr. Company | Gradual release structures for chewing gum |
| US4978537A (en) * | 1989-04-19 | 1990-12-18 | Wm. Wrigley Jr. Company | Gradual release structures for chewing gum |
| US5198251A (en) * | 1989-04-19 | 1993-03-30 | Wm. Wrigley Jr. Company | Gradual release structures for chewing gum |
| US5229148A (en) * | 1989-04-19 | 1993-07-20 | Wm. Wrigley Jr. Company | Method of combining active ingredients with polyvinyl acetates |
| US5154939A (en) * | 1989-04-19 | 1992-10-13 | Wm. Wrigley Jr. Company | Use of salt to improve extrusion encapsulation of chewing gum ingredients |
| NZ235372A (en) * | 1989-10-10 | 1992-05-26 | Wrigley W M Jun Co | Slow release delivery system made by fibre melt spinning techniques producing a fibre about 1mm diameter, exterior is substantially wall material and core mostly active agent dispersed through the fibre material which is porous overall |
| US5128155A (en) * | 1990-12-20 | 1992-07-07 | Wm. Wrigley Jr. Company | Flavor releasing structures for chewing gum |
| WO2004073685A1 (en) * | 2003-02-20 | 2004-09-02 | Constant Research & Development Limited | Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor |
| US7771528B2 (en) * | 2007-08-16 | 2010-08-10 | The United States Of America As Represented By The Secretary Of Agriculture | Processing for producing zein articles with limited solubility |
| EP2707420A4 (en) * | 2011-05-13 | 2014-10-29 | Univ Alberta | POLYMERS AND PLASTICS FROM ANIMAL PROTEINS |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2591133A (en) * | 1950-05-29 | 1952-04-01 | California Inst Res Found | Method of producing gelatin derivative |
-
0
- NL NL256065D patent/NL256065A/xx unknown
- NL NL125158D patent/NL125158C/xx active
-
1959
- 1959-10-01 US US843631A patent/US3028308A/en not_active Expired - Lifetime
-
1960
- 1960-09-14 GB GB31691/60A patent/GB948008A/en not_active Expired
- 1960-09-21 ES ES0261175A patent/ES261175A1/es not_active Expired
- 1960-09-23 DE DE19601445105 patent/DE1445105A1/de active Pending
- 1960-09-26 BE BE595413A patent/BE595413A/fr unknown
- 1960-09-30 CH CH1102860A patent/CH394494A/de unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE1445105A1 (de) | 1969-01-09 |
| US3028308A (en) | 1962-04-03 |
| BE595413A (fr) | 1961-03-27 |
| CH394494A (de) | 1965-06-30 |
| NL125158C (es) | |
| NL256065A (es) | |
| GB948008A (en) | 1964-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES261175A1 (es) | Procedimiento para la preparaciën de un vector farmaceutico | |
| JP3010562B2 (ja) | 徐放性調剤単位 | |
| US5183662A (en) | Controlled drug release composition | |
| US2897121A (en) | Pharmaceutical composition | |
| US3574820A (en) | Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix | |
| US5340589A (en) | Low solubility drug-coated bead compositions | |
| US3362881A (en) | Sustained release tablet and method of manufacturing same | |
| US2656298A (en) | Therapeutic product | |
| ES445014A1 (es) | Procedimiento de obtencion de preparaciones farmaceuticas noamargas, para la administracion oral. | |
| JPH03184920A (ja) | 酸感受性蛋白性物質の経口投与用医薬組成物 | |
| AU657573B2 (en) | Oral preparation for release in lower digestive tracts | |
| JPS5883618A (ja) | ニトロフラントイン投与剤 | |
| US4189469A (en) | Pharmaceutical compositions | |
| US3018221A (en) | Penicillin-sulfonamide tablet | |
| US3891755A (en) | Dosage formulation for erythromycin cetyl sulfate | |
| JPS62209025A (ja) | 即効性を有した成分を持続的に放出する医薬合成品およびその調合方法 | |
| US3144387A (en) | Anti-inflammatory compositions | |
| US3066075A (en) | Compositions comprising amphetamine and carboxymethyl cellulose in chemically combined form | |
| US2888382A (en) | Therapeutic composition and process | |
| JPH03128380A (ja) | Ｎ↑５，ｎ↑１↑０―メチレン―５，６，７，８―テトラヒドロ葉酸の塩およびその製造方法 | |
| CN112704671A (zh) | 一种阿莫西林克拉维酸钾胶囊及其制备方法 | |
| US3130126A (en) | Oral pharmaceutical products prepared with carboxymethyl benzyl dextran having a low carboxymethyl d. s. of 0.15 | |
| CN118384121B (zh) | 左炔诺孕酮肠溶片及其制备方法 | |
| AU633525B2 (en) | Enhancers for biosynthetic interferon and compositions containing them as well as preparations for making aids asymptomatic and curing aids and compositions therefor | |
| US5260056A (en) | Composition for enhancing biosynthesis of interferon |